First Patient Dosed in Open-label Trial of MarzAA

First Patient Dosed in Open-label Trial of MarzAA

294734

First Patient Dosed in Open-label Trial of MarzAA

The first participant has been dosed in a Phase 1/2 clinical trial evaluating marzeptacog alfa activated (MarzAA) to treat bleeding episodes in patients with factor VII (FVII) deficiency, Glanzmann thrombasthenia, and hemophilia A with inhibitors receiving treatment with Hemlibra (emicizumab). The open-label study, called MAA-202 (NCT04548791), is being sponsored by the investigational therapy’s developer, Catalyst Biosciences, and is currently enrolling up to 24 patients, ages 12 and older, at the Children’s Hospital of Michigan and…

You must be logged in to read/download the full post.